Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis; A Nonrandomized Controlled Trial

NCT07000630 is registered in ClinicalTrials.gov with Peking University First Hospital as lead sponsor.

NCT NCT07000630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07000630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis; A Nonrandomized Controlled Trial
Lead sponsor
Peking University First Hospital
Phase
Not applicable
Overall status
Terminated
Start date
June 20, 2025
Completion date
December 1, 2025
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

palmoplantar pustulosis